PlumX Metrics
Embed PlumX Metrics

CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions

Current Oncology Reports, ISSN: 1534-6269, Vol: 21, Issue: 3, Page: 25
2019
  • 132
    Citations
  • 0
    Usage
  • 187
    Captures
  • 4
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    132
  • Captures
    187
  • Mentions
    4
    • News Mentions
      4
      • News
        4

Most Recent News

Current Approaches in Optimizing Targeted Agents and Sequencing Decisions for HR+ Breast Cancer

Medscape recently asked breast cancer experts how they sequence targeted agents for HR+, HER2/neu-negative (also known as ErbB-2) metastatic breast cancer. Joining us today are

Review Description

Purpose of Review: To describe the clinical role of CDK 4/6 inhibitors in hormone receptor-positive (HR+) metastatic breast cancer (HR+ MBC) as well as current controversies and evolving areas of research. Recent Findings: Palbociclib, ribociclib, and abemaciclib are each approved in combination with an aromatase inhibitor or fulvestrant for HR+ MBC. Abemaciclib is also approved as monotherapy for pre-treated patients. Key questions in the field include whether all patients with HR+ MBC should receive a CDK 4/6 inhibitor up front versus later line, impact on overall survival, role of continued CDK 4/6 blockade, mechanism of clinical resistance, and treatment sequencing. Summary: The development of CDK 4/6 inhibitors has changed the therapeutic management of HR+ MBC. Additional research is needed to determine optimal treatment sequencing, understand mechanisms governing resistance, and develop novel therapeutic strategies to circumvent or overcome clinical resistance and further improve the outcomes of patients with MBC.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know